Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 482

1.

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.

Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B, Salmon SE.

Blood. 2002 May 1;99(9):3163-8.

2.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.

Blood. 2003 Mar 15;101(6):2144-51. Epub 2002 Nov 27.

3.

Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.

Zervas K, Pouli A, Perifanis V, Papanastasiou K, Chatziyianni M, Mitsouli C, Maniatis A.

Eur J Haematol. 1996 Aug;57(2):142-8.

PMID:
8856091
4.

Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.

Cavo M, Benni M, Ronconi S, Fiacchini M, Gozzetti A, Zamagni E, Cellini C, Tosi P, Baccarani M, Tura S; Writing Committee of the "Bologna 90" Clinical Trial.

Haematologica. 2002 Sep;87(9):934-42.

5.

[Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].

Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.

Srp Arh Celok Lek. 1996 Nov-Dec;124(11-12):292-6. Serbian.

PMID:
9132962
6.

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).

Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, Lokhorst H, van der Lelie J, Dohner H, Gerhartz H, Segeren CM, Willemze R, Lowenberg B; European Organization for Research and Treatment of Cancer (EORTC); Leukaemia Cooperative Group (LCG); Dutch Haemato-Oncology Cooperative Study Group (HOVON).

Br J Haematol. 2001 Dec;115(4):895-902.

PMID:
11843823
7.

A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7.

Shustik C, Belch A, Robinson S, Rubin SH, Dolan SP, Kovacs MJ, Grewal KS, Walde D, Barr R, Wilson J, Gill K, Vickars L, Rudinskas L, Sicheri DA, Wilson K, Djurfeldt M, Shepherd LE, Ding K, Meyer RM.

Br J Haematol. 2007 Jan;136(2):203-11.

PMID:
17233817
10.
11.

Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.

Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.

Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.

PMID:
19487425
12.

Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.

Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, Samlowski W.

J Clin Oncol. 1998 Mar;16(3):890-6.

PMID:
9508170
13.

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azaïs I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P.

J Clin Oncol. 2009 Aug 1;27(22):3664-70. doi: 10.1200/JCO.2008.21.0948. Epub 2009 May 18.

PMID:
19451428
15.

Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).

Adam Z, Elbl L, Vorlicek J, Hájek R, Hájek D, Hejlová N, Králová E, Novotná H.

Acta Med Austriaca. 1994;21(4):111-5.

PMID:
7871966
16.

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.

J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added].

PMID:
16432076
17.

[Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].

Yuan ZG, Hou J, Wang DX, Fu WJ, Chen YB, Xi H.

Ai Zheng. 2007 Dec;26(12):1369-72. Chinese.

PMID:
18076804
18.
19.

Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.

Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA.

Am J Hematol. 2007 Dec;82(12):1071-5.

20.

[Progress in the treatment of multiple myeloma].

Wada M, Mizoguchi H.

Gan To Kagaku Ryoho. 1997 Jul;24(9):1079-88. Review. Japanese.

PMID:
9239160

Supplemental Content

Support Center